Filtered By:
Source: The Lancet Diabetes and Endocrinology
Condition: Heart Attack
This page shows you your search results in order of date.
Order by Relevance | Date
Total 31 results found since Jan 2013.
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
We examined the association between glucose-lowering medications and a broad range of cardiovascular outcomes, and assessed the strength of evidence for these associations.MethodsFor this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications. Cardiovascular outcomes examined included major adverse cardiovascular events, cardiovascular death, myocardial infarction, stroke, heart failure, unstable angina, and atrial fibrillation. For each meta-analysis, we estimat...
Source: The Lancet Diabetes and Endocrinology - January 30, 2020 Category: Endocrinology Source Type: research
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Publication date: Available online 7 January 2020Source: The Lancet Diabetes & EndocrinologyAuthor(s): Hertzel C Gerstein, Robert Hart, Helen M Colhoun, Rafael Diaz, Mark Lakshmanan, Fady T Botros, Jeffrey Probstfield, Matthew C Riddle, Lars Rydén, Charles Messan Atisso, Leanne Dyal, Stephanie Hall, Alvaro Avezum, Jan Basile, Ignacio Conget, William C Cushman, Nicolae Hancu, Markolf Hanefeld, Petr Jansky, Matyas KeltaiSummaryBackgroundCardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researchi...
Source: The Lancet Diabetes and Endocrinology - January 9, 2020 Category: Endocrinology Source Type: research
Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants
Publication date: January 2020Source: The Lancet Diabetes & Endocrinology, Volume 8, Issue 1Author(s): Nelson Wang, Jordan Fulcher, Nishan Abeysuriya, Laura Park, Shejil Kumar, Gian Luca Di Tanna, Ian Wilcox, Anthony Keech, Anthony Rodgers, Sean LalSummaryBackgroundThe benefits of LDL cholesterol-lowering treatment for the prevention of atherosclerotic cardiovascular disease are well established. However, the extent to which these effects differ by baseline LDL cholesterol, atherosclerotic cardiovascular disease risk, and the presence of comorbidities remains uncertain.MethodsWe did a systematic literature search (MEDLINE,...
Source: The Lancet Diabetes and Endocrinology - December 18, 2019 Category: Endocrinology Source Type: research
Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial
In this report, we did a post-hoc analysis of cardiovascular and renal outcomes over 10 years following randomisation, including a 5 years post-intervention follow-up. As in the original trial, the primary endpoint was a composite of first cardiovascular event, including cardiovascular mortality, cardiovascular morbidity (non-fatal myocardial infarction and non-fatal stroke), revascularisation, and non-traumatic amputation, up to Dec 31, 2014. Analyses were based on the intention-to-treat principle. ADDITION-Europe is registered with ClinicalTrials.gov, NCT00237549.Findings343 general practices were randomly assigned to ro...
Source: The Lancet Diabetes and Endocrinology - November 21, 2019 Category: Endocrinology Source Type: research
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
Publication date: Available online 31 October 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Michael R McClung, Michelle L O'Donoghue, Socrates E Papapoulos, Henry Bone, Bente Langdahl, Kenneth G Saag, Ian R Reid, Douglas P Kiel, Ilaria Cavallari, Marc P Bonaca, Stephen D Wiviott, Tobias de Villiers, Xu Ling, Kurt Lippuner, Toshitaka Nakamura, Jean-Yves Reginster, Jose Adolfo Rodriguez-Portales, Christian Roux, José Zanchetta, Cristiano A F ZerbiniSummaryBackgroundOdanacatib, a cathepsin K inhibitor, reduces bone resorption while maintaining bone formation. Previous work has shown that odanacatib increases bone...
Source: The Lancet Diabetes and Endocrinology - November 2, 2019 Category: Endocrinology Source Type: research
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Publication date: Available online 14 August 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurraySummaryBackgroundGlucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes reported. We aimed to synthesise the available evidence by doing a systematic review and meta-analysis of cardiovascular ou...
Source: The Lancet Diabetes and Endocrinology - August 15, 2019 Category: Endocrinology Source Type: research
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Publication date: Available online 1 July 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Kausik K Ray, Helen M Colhoun, Michael Szarek, Marie Baccara-Dinet, Deepak L Bhatt, Vera A Bittner, Andrzej J Budaj, Rafael Diaz, Shaun G Goodman, Corinne Hanotin, Robert A Harrington, J Wouter Jukema, Virginie Loizeau, Renato D Lopes, Angèle Moryusef, Jan Murin, Robert Pordy, Arsen D Ristic, Matthew T Roe, José TuñónSummaryBackgroundAfter acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4–1·8 mmol/L with ezetimibe or statins reduces...
Source: The Lancet Diabetes and Endocrinology - July 2, 2019 Category: Endocrinology Source Type: research
Glucose screening in pregnancy and future risk of cardiovascular disease in women: a retrospective, population-based cohort study
Publication date: Available online 27 March 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Ravi Retnakaran, Baiju R ShahSummaryBackgroundIn studies to date, gestational diabetes has consistently been associated with an increased future risk of cardiovascular disease, irrespective of the antepartum screening protocol or diagnostic criteria by which gestational diabetes is diagnosed. We reasoned that the resultant heterogeneity in the severity of dysglycaemia in women with gestational diabetes suggests that the relationship between gestational glycaemia and subsequent cardiovascular disease probably extends into t...
Source: The Lancet Diabetes and Endocrinology - March 28, 2019 Category: Endocrinology Source Type: research
Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study
Publication date: Available online 28 February 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Onyebuchi E Okosieme, Peter N Taylor, Carol Evans, Dan Thayer, Aaron Chai, Ishrat Khan, Mohd S Draman, Brian Tennant, John Geen, Adrian Sayers, Robert French, John H Lazarus, Lakdasa D Premawardhana, Colin M DayanSummaryBackgroundGraves' disease is routinely treated with antithyroid drugs, radioiodine, or surgery, but whether the choice of initial therapy influences long-term outcomes is uncertain. We evaluated cardiovascular morbidity and mortality according to the method and effectiveness of primary therapy in Graves'...
Source: The Lancet Diabetes and Endocrinology - March 1, 2019 Category: Endocrinology Source Type: research
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden
Publication date: Available online 5 December 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Henrik Svanström, Peter Ueda, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn PasternakSummaryBackgroundTrial evidence shows that the glucagon-like peptide-1 receptor agonist liraglutide significantly reduces the risk of major cardiovascular events among patients with type 2 diabetes who have established cardiovascular disease or are at high cardiovascular risk. We aimed to assess the cardiovascular effectiveness of liraglutide in rou...
Source: The Lancet Diabetes and Endocrinology - December 6, 2018 Category: Endocrinology Source Type: research
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
Publication date: Available online 2 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Marc P Bonaca, J Antonio Gutierrez, Christopher Cannon, Robert Giugliano, Michael Blazing, Jeong-Gun Park, Jennifer White, Andrew Tershakovec, Eugene BraunwaldSummaryBackgroundPolyvascular disease and type 2 diabetes are each associated with increased cardiovascular risk, but whether these risks are additive is unknown. In this exploratory analysis of a randomised trial, we explored the long-term cardiovascular risk associated with polyvascular disease, type 2 diabetes, and their combination in patients with acute corona...
Source: The Lancet Diabetes and Endocrinology - November 3, 2018 Category: Endocrinology Source Type: research
Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988 –2014
Publication date: Available online 27 February 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Mohammed K Ali, Kai McKeever Bullard, Sharon Saydah, Giuseppina Imperatore, Edward W Gregg Background There is controversy over the usefulness of prediabetes as a diagnostic label. Using data from US National Health and Nutrition Examination Surveys (NHANES) between 1988 and 2014, we examined the cardiovascular and renal burdens in adults with prediabetes over time and compared patterns with other glycaemic status groups. Methods We analysed cross-sectional survey data from non-pregnant adults aged 20 years an...
Source: The Lancet Diabetes and Endocrinology - February 28, 2018 Category: Endocrinology Source Type: research
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
Publication date: Available online 6 December 2017 Source:The Lancet Diabetes & Endocrinology Author(s): M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Peter Öhman, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular...
Source: The Lancet Diabetes and Endocrinology - December 6, 2017 Category: Endocrinology Source Type: research
Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study
Publication date: Available online 9 November 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Gregory L Hundemer, Gary C Curhan, Nicholas Yozamp, Molin Wang, Anand Vaidya Background Mineralocorticoid receptor (MR) antagonists are the recommended medical therapy for primary aldosteronism. Whether this recommendation effectively reduces cardiometabolic risk is not well understood. We aimed to investigate the risk of incident cardiovascular events in patients with primary aldosteronism treated with MR antagonists compared with patients with essential hypertension. Methods We did a cohort study using patien...
Source: The Lancet Diabetes and Endocrinology - November 10, 2017 Category: Endocrinology Source Type: research
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial
This study is registered with ClinicalTrials.gov, number NCT00300976. Findings Between June 16, 2006, and March 31, 2009, 2542 eligible patients were randomly assigned to intensive therapy or conventional therapy (1271 in each group) and followed up for a median of 8·5 years (IQR 7·3–9·0). Two patients in the intensive therapy group were found to be ineligible after randomisation and were excluded from the analyses. During the intervention period, mean HbA1c, systolic blood pressure, diastolic blood pressure, and LDL cholesterol concentrations were significantly lower in the intensive therapy group than in the convent...
Source: The Lancet Diabetes and Endocrinology - October 25, 2017 Category: Endocrinology Source Type: research
